1. Home
  2. TRDA
  3. TRDA News

Latest Entrada Therapeutics Inc. (TRDA) News on November 25, 2025

Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates
TRDA

Zacks

19 days ago

Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates

Entrada Therapeutics Reports Third Quarter 2025 Financial Results
TRDA

GlobeNewswire

19 days ago

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
TRDA

GlobeNewswire

6 months ago

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TRDA

GlobeNewswire

6 months ago

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Entrada’s Phase I/II trial of DMD treatment authorised to begin in EU
TRDA

Clinical Trials Arena

6 months ago

Entrada’s Phase I/II trial of DMD treatment authorised to begin in EU

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
TRDA

GlobeNewswire

6 months ago

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results
TRDA

Simply Wall St.

6 months ago

Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates
TRDA

Zacks

7 months ago

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

Entrada Therapeutics Reports First Quarter 2025 Financial Results
TRDA

GlobeNewswire

7 months ago

Entrada Therapeutics Reports First Quarter 2025 Financial Results

Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release
TRDA

Zacks

7 months ago

Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Arvinas, Entrada cut staff; Merck builds US hub for Keytruda
TRDA

BioPharma Dive

7 months ago

Arvinas, Entrada cut staff; Merck builds US hub for Keytruda

Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for
TRDA

Zacks

7 months ago

Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for

Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?
TRDA

Zacks

7 months ago

Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?

Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment
TRDA

Clinical Trials Arena

8 months ago

Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment

TRDA

MT Newswires

8 months ago

Entrada Therapeutics Duchenne Muscular Dystrophy Investigational Treatment Study Gets Approval in UK

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
TRDA

GlobeNewswire

8 months ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next
TRDA

Simply Wall St.

9 months ago

Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next

Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates
TRDA

Zacks

9 months ago

Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
TRDA

GlobeNewswire

9 months ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA
TRDA

Zacks

9 months ago

Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA

AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch
TRDA

BioPharma Dive

9 months ago

AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch

FDA removes clinical hold on Entrada’s Duchenne therapy
TRDA

Clinical Trials Arena

9 months ago

FDA removes clinical hold on Entrada’s Duchenne therapy

TRDA

MT Newswires

9 months ago

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday

TRDA

MT Newswires

9 months ago

Entrada Therapeutics Says FDA Lifted Clinical Hold on ENTR-601-44; Shares Advance Premarket

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
TRDA

GlobeNewswire

9 months ago

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now
TRDA

Insider Monkey

9 months ago

Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now

Entrada gets UK MHRA authorisation to begin Phase I/II trial of DMD treatment
TRDA

Clinical Trials Arena

10 months ago

Entrada gets UK MHRA authorisation to begin Phase I/II trial of DMD treatment

TRDA

MT Newswires

10 months ago

Entrada Therapeutics Gets UK Approval for Phase 1/2 Study of Duchenne Muscular Dystrophy Treatment

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
TRDA

GlobeNewswire

10 months ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Azenta Announces the Election of Dipal Doshi to its Board of Directors
TRDA

PR Newswire

10 months ago

Azenta Announces the Election of Dipal Doshi to its Board of Directors

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
TRDA

Simply Wall St.

10 months ago

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Best Momentum Stocks to Buy for December 30th
TRDA

Zacks

a year ago

Best Momentum Stocks to Buy for December 30th

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
TRDA

GlobeNewswire

a year ago

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating
TRDA

TipRanks

a year ago

Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating

TRDA

MT Newswires

a year ago

Roth Initiates Entrada Therapeutics at Buy

Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why
TRDA

Zacks

a year ago

Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why

TRDA

MT Newswires

a year ago

Entrada Therapeutics Insider Sold Shares Worth $339,281, According to a Recent SEC Filing

Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations
TRDA

Simply Wall St.

a year ago

Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates
TRDA

Zacks

a year ago

Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates

Entrada Therapeutics Reports Third Quarter 2024 Financial Results
TRDA

GlobeNewswire

a year ago

Entrada Therapeutics Reports Third Quarter 2024 Financial Results

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
TRDA

GlobeNewswire

a year ago

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
TRDA

GlobeNewswire

a year ago

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
TRDA

GlobeNewswire

a year ago

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Forecast: Analysts Think Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Business Prospects Have Improved Drastically
TRDA

Simply Wall St.

a year ago

Forecast: Analysts Think Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Business Prospects Have Improved Drastically

AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer
TRDA

Zacks

a year ago

AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer

Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY
TRDA

Zacks

a year ago

Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY

Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination
TRDA

Zacks

a year ago

Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination

Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates
TRDA

Zacks

a year ago

Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates

Entrada Therapeutics Reports Second Quarter 2024 Financial Results
TRDA

GlobeNewswire

a year ago

Entrada Therapeutics Reports Second Quarter 2024 Financial Results

Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B
TRDA

Zacks

a year ago

Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B

Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid
TRDA

Zacks

a year ago

Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid

Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View
TRDA

Zacks

a year ago

Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View

Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook
TRDA

Zacks

a year ago

Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook

Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View
TRDA

Zacks

a year ago

Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2
TRDA

Zacks

a year ago

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak
TRDA

Zacks

a year ago

Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak

Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line
TRDA

Zacks

a year ago

Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line

Is Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Recent Price Movement Underpinned By Its Weak Fundamentals?
TRDA

Simply Wall St.

a year ago

Is Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Recent Price Movement Underpinned By Its Weak Fundamentals?

Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View
TRDA

Zacks

a year ago

Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View

Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash
TRDA

Zacks

a year ago

Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash

JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View
TRDA

Zacks

a year ago

JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View

United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates
TRDA

Zacks

a year ago

United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates

Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View
TRDA

Zacks

a year ago

Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View

Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High?
TRDA

Zacks

a year ago

Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High?

Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last?
TRDA

Zacks

a year ago

Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last?

Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength?
TRDA

Zacks

a year ago

Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength?

Best Momentum Stocks to Buy for July 9th
TRDA

Zacks

a year ago

Best Momentum Stocks to Buy for July 9th

With 40% ownership, Entrada Therapeutics, Inc. (NASDAQ:TRDA) has piqued the interest of institutional investors
TRDA

Simply Wall St.

a year ago

With 40% ownership, Entrada Therapeutics, Inc. (NASDAQ:TRDA) has piqued the interest of institutional investors

TRDA

MT Newswires

a year ago

Entrada Therapeutics Signs Securities Purchase Agreement of 3.4 Million Common Shares in Registered Direct Offering

Entrada Therapeutics Announces $100 Million Registered Direct Offering
TRDA

GlobeNewswire

a year ago

Entrada Therapeutics Announces $100 Million Registered Direct Offering

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
TRDA

GlobeNewswire

a year ago

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
TRDA

GlobeNewswire

a year ago

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet
TRDA

Zacks

2 years ago

Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet

TRDA

MT Newswires

2 years ago

Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing

TRDA

Argus Research

2 years ago

Daily – Vickers Top Buyers & Sellers for 05/17/2024

Director Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA)
TRDA

GuruFocus.com

2 years ago

Director Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA)

TRDA

MT Newswires

2 years ago

Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
TRDA

GlobeNewswire

2 years ago

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Entrada Therapeutics First Quarter 2024 Earnings: Beats Expectations
TRDA

Simply Wall St.

2 years ago

Entrada Therapeutics First Quarter 2024 Earnings: Beats Expectations

Entrada Therapeutics Reports First Quarter 2024 Financial Results
TRDA

GlobeNewswire

2 years ago

Entrada Therapeutics Reports First Quarter 2024 Financial Results

Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA)
TRDA

GuruFocus.com

2 years ago

Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA)

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates
TRDA

Simply Wall St.

2 years ago

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates

Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials
TRDA

GuruFocus.com

2 years ago

Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
TRDA

GlobeNewswire

2 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Entrada Therapeutics to Present at Upcoming Investor Conferences
TRDA

GlobeNewswire

2 years ago

Entrada Therapeutics to Present at Upcoming Investor Conferences

TRDA

GlobeNewswire

2 years ago

Employers Holdings, Inc. Schedules Fourth Quarter and Full-Year 2023 Earnings Release and Conference Call

‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 Stocks
TRDA

TipRanks

2 years ago

‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 Stocks

American Couples Should Count on Needing At Least This Much Money For Retirement Each Month
TRDA

SmartAsset

2 years ago

American Couples Should Count on Needing At Least This Much Money For Retirement Each Month

TRDA

Associated Press Finance

2 years ago

Fair Isaac: Fiscal Q1 Earnings Snapshot

Hudson Pacific Properties Announces 2023 Dividend Tax Treatment
TRDA

Business Wire

2 years ago

Hudson Pacific Properties Announces 2023 Dividend Tax Treatment

Amerant Reports Fourth Quarter 2023 and Full-Year 2023 Results
TRDA

Business Wire

2 years ago

Amerant Reports Fourth Quarter 2023 and Full-Year 2023 Results

SpartanNash Implements New Food Traceability Program, Strengthening Safety and Transparency Throughout Its Global Supply Chain
TRDA

PR Newswire

2 years ago

SpartanNash Implements New Food Traceability Program, Strengthening Safety and Transparency Throughout Its Global Supply Chain

Olympic Steel Promotes Anthony G. Dominic to Vice President of Safety, Health and Environment
TRDA

Business Wire

2 years ago

Olympic Steel Promotes Anthony G. Dominic to Vice President of Safety, Health and Environment

Invesco Municipal Opportunity Trust's Dividend Analysis
TRDA

GuruFocus.com

2 years ago

Invesco Municipal Opportunity Trust's Dividend Analysis

ProPetro Announces Fourth Quarter 2023 Earnings Call
TRDA

Business Wire

2 years ago

ProPetro Announces Fourth Quarter 2023 Earnings Call

Lemonade Announces Extension of CAC Financing Agreement with General Catalyst
TRDA

Business Wire

2 years ago

Lemonade Announces Extension of CAC Financing Agreement with General Catalyst

EMPLOYERS® Named GHLA's Choice for Workers' Comp
TRDA

Business Wire

2 years ago

EMPLOYERS® Named GHLA's Choice for Workers' Comp

Data Analytics Stocks Q3 Recap: Benchmarking Domo (NASDAQ:DOMO)
TRDA

StockStory

2 years ago

Data Analytics Stocks Q3 Recap: Benchmarking Domo (NASDAQ:DOMO)

PALISADES ANNOUNCES NEW FOUND INTERCEPTS AT HONEYPOT ZONE AT QUEENSWAY PROJECT
TRDA

CNW Group

2 years ago

PALISADES ANNOUNCES NEW FOUND INTERCEPTS AT HONEYPOT ZONE AT QUEENSWAY PROJECT

Is Now An Opportune Moment To Examine Health Catalyst, Inc. (NASDAQ:HCAT)?
TRDA

Simply Wall St.

2 years ago

Is Now An Opportune Moment To Examine Health Catalyst, Inc. (NASDAQ:HCAT)?

Share on Social Networks: